{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:55:07Z","timestamp":1789012507841,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["Damon Runyon Clinical Investigator Award"],"award-info":[{"award-number":["Damon Runyon Clinical Investigator Award"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA242861"],"award-info":[{"award-number":["R21CA242861"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA227388-02"],"award-info":[{"award-number":["R01CA227388-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA239347"],"award-info":[{"award-number":["F31CA239347"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100008536","name":"Amazon Web Services","doi-asserted-by":"publisher","award":["AWS Cloud Credits for Research Program"],"award-info":[{"award-number":["AWS Cloud Credits for Research Program"]}],"id":[{"id":"10.13039\/100008536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute","doi-asserted-by":"publisher","award":["5T32HG002295-15"],"award-info":[{"award-number":["5T32HG002295-15"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Claudia Adams Barr Program for Innovative Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41588-020-00739-1","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T12:09:57Z","timestamp":1606133397000},"page":"1373-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Integrated molecular drivers coordinate biological and clinical states in melanoma"],"prefix":"10.1038","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-2054","authenticated-orcid":false,"given":"Jake R.","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaro","family":"Taylor-Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"AlDubayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-5335","authenticated-orcid":false,"given":"Natalie","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-0616","authenticated-orcid":false,"given":"Jason L.","family":"Weirather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1290-9276","authenticated-orcid":false,"given":"Rizwan","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-4103","authenticated-orcid":false,"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Stephen Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"739_CR1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"739_CR2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network.","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"739_CR3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"739_CR4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107\u2013114 (2012).","journal-title":"N. Engl. J. Med."},{"key":"739_CR5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"739_CR6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"739_CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"739_CR8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"739_CR9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"739_CR10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006\u20131014 (2012).","journal-title":"Nat. Genet."},{"key":"739_CR11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"H Cirenajwis","year":"2017","unstructured":"Cirenajwis, H. et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol. Oncol. 11, 438\u2013451 (2017).","journal-title":"Mol. Oncol."},{"key":"739_CR12","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI95351","volume":"128","author":"J Nsengimana","year":"2018","unstructured":"Nsengimana, J. et al. \u03b2-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J. Clin. Invest. 128, 2048\u20132063 (2018).","journal-title":"J. Clin. Invest."},{"key":"739_CR13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996\u20131002 (2015).","journal-title":"Nat. Genet."},{"key":"739_CR14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94\u2013109 (2014).","journal-title":"Cancer Discov."},{"key":"739_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition. Cancer Discov. 4, 61\u201368 (2014).","journal-title":"Cancer Discov."},{"key":"739_CR16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"739_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175\u2013180 (2017).","journal-title":"Nature"},{"key":"739_CR18","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"739_CR19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"739_CR20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41588-019-0572-y","volume":"52","author":"F Dietlein","year":"2020","unstructured":"Dietlein, F. et al. Identification of cancer driver genes based on nucleotide context. Nat. Genet. 52, 208\u2013218 (2020).","journal-title":"Nat. Genet."},{"key":"739_CR21","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0994-0","volume":"17","author":"L Mularoni","year":"2016","unstructured":"Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A. & L\u00f3pez-Bigas, N. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 17, 128 (2016).","journal-title":"Genome Biol."},{"key":"739_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, 1\u201316 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"739_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","volume":"504","author":"CM Johannessen","year":"2013","unstructured":"Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138\u2013142 (2013).","journal-title":"Nature"},{"key":"739_CR24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"739_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","volume":"9","author":"Q Yu","year":"2006","unstructured":"Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23\u201332 (2006).","journal-title":"Cancer Cell"},{"key":"739_CR26","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland, C. R., Richard Boland, C. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073\u20132087.e3 (2010).","journal-title":"Gastroenterology"},{"key":"739_CR27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cell.2018.07.034","volume":"174","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 174, 1034\u20131035 (2018).","journal-title":"Cell"},{"key":"739_CR28","doi-asserted-by":"crossref","first-page":"24227","DOI":"10.1074\/jbc.M414305200","volume":"280","author":"T Alliston","year":"2005","unstructured":"Alliston, T. et al. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1. J. Biol. Chem. 280, 24227\u201324237 (2005).","journal-title":"J. Biol. Chem."},{"key":"739_CR29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1074\/jbc.M410836200","volume":"280","author":"S Buonamici","year":"2005","unstructured":"Buonamici, S. et al. EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J. Biol. Chem. 280, 428\u2013436 (2005).","journal-title":"J. Biol. Chem."},{"key":"739_CR30","volume":"7","author":"JJ Lee","year":"2015","unstructured":"Lee, J. J. et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-na\u00efve patient melanomas. Clin. Epigenet. 7, 59 (2015).","journal-title":"Clin. Epigenet."},{"key":"739_CR31","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies, A. M. et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242\u20133249 (2012).","journal-title":"Clin. Cancer Res."},{"key":"739_CR32","first-page":"9502","volume":"34","author":"K Flaherty","year":"2016","unstructured":"Flaherty, K. et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma. J. Clin. Orthod. 34, 9502\u20139502 (2016).","journal-title":"J. Clin. Orthod."},{"key":"739_CR33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann. Oncol. 28, 1631\u20131639 (2017).","journal-title":"Ann. Oncol."},{"key":"739_CR34","doi-asserted-by":"crossref","first-page":"e1500447","DOI":"10.1126\/sciadv.1500447","volume":"1","author":"C Kadoch","year":"2015","unstructured":"Kadoch, C. & Crabtree, G. R. Mammalian SWI\/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447 (2015).","journal-title":"Sci. Adv."},{"key":"739_CR35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"739_CR36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/ng.3427","volume":"47","author":"R Arafeh","year":"2015","unstructured":"Arafeh, R. et al. Recurrent inactivating RASA2 mutations in melanoma. Nat. Genet. 47, 1408\u20131410 (2015).","journal-title":"Nat. Genet."},{"key":"739_CR37","first-page":"58","volume":"1776","author":"L van der Weyden","year":"2007","unstructured":"van der Weyden, L. & Adams, D. J. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 1776, 58\u201385 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"739_CR38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.gastro.2005.03.051","volume":"129","author":"K Akino","year":"2005","unstructured":"Akino, K. et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129, 156\u2013169 (2005).","journal-title":"Gastroenterology"},{"key":"739_CR39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6602854","volume":"93","author":"M Endoh","year":"2005","unstructured":"Endoh, M. et al. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer 93, 1395\u20131399 (2005).","journal-title":"Br. J. Cancer"},{"key":"739_CR40","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin, J. A., Busam, K., Pinkel, D. & Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340\u20134346 (2006).","journal-title":"J. Clin. Oncol."},{"key":"739_CR41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204\u2013220.e15 (2017).","journal-title":"Cancer Cell"},{"key":"739_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell, F. et al. Whole-genome landscape of mucosal melanomas reveals diverse drivers and therapeutic targets. Nat. Commun. 10, 3163 (2019).","journal-title":"Nat. Commun."},{"key":"739_CR43","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"739_CR44","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"739_CR45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227\u2013238.e3 (2018).","journal-title":"Cell Rep."},{"key":"739_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"739_CR47","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/bioinformatics\/btv408","volume":"31","author":"JS Gehring","year":"2015","unstructured":"Gehring, J. S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31, 3673\u20133675 (2015).","journal-title":"Bioinformatics"},{"key":"739_CR48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153\u2013158 (2007).","journal-title":"Nature"},{"key":"739_CR49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"739_CR50","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776\u20131782 (2012).","journal-title":"Br. J. Cancer"},{"key":"739_CR51","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms, K. M. et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).","journal-title":"Breast Cancer Res."},{"key":"739_CR52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak, N. J. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2, 366\u2013375 (2012).","journal-title":"Cancer Discov."},{"key":"739_CR53","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Res. 72, 5454\u20135462 (2012).","journal-title":"Cancer Res."},{"key":"739_CR54","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard, A. M. et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res 3, 9 (2015).","journal-title":"Biomark. Res"},{"key":"739_CR55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"739_CR56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"A Alexandrov","year":"2020","unstructured":"Alexandrov, A. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"739_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"739_CR58","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","volume":"40","author":"DJ McCarthy","year":"2012","unstructured":"McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288\u20134297 (2012).","journal-title":"Nucleic Acids Res."},{"key":"739_CR59","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"739_CR60","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. 49, 1476\u20131486 (2017).","journal-title":"Nat. Genet."},{"key":"739_CR61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ije\/dyr238","volume":"41","author":"AE Jaffe","year":"2012","unstructured":"Jaffe, A. E. et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int. J. Epidemiol. 41, 200\u2013209 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"739_CR62","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363\u20131369 (2014).","journal-title":"Bioinformatics"},{"key":"739_CR63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.dnarep.2008.11.014","volume":"8","author":"T Tsukuda","year":"2009","unstructured":"Tsukuda, T. et al. INO80-dependent chromatin remodeling regulates early and late stages of mitotic homologous recombination. DNA Repair 8, 360\u2013369 (2009).","journal-title":"DNA Repair"},{"key":"739_CR64","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.celrep.2017.04.051","volume":"19","author":"CA Lademann","year":"2017","unstructured":"Lademann, C. A., Renkawitz, J., Pfander, B. & Jentsch, S. The INO80 complex removes H2A.Z to promote presynaptic filament formation during homologous recombination. Cell Rep. 19, 1294\u20131303 (2017).","journal-title":"Cell Rep."},{"key":"739_CR65","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/nar\/gkv160","volume":"43","author":"A Bakr","year":"2015","unstructured":"Bakr, A. et al. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 43, 3154\u20133166 (2015).","journal-title":"Nucleic Acids Res."},{"key":"739_CR66","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1093\/nar\/gkt134","volume":"41","author":"AL Fenton","year":"2013","unstructured":"Fenton, A. L., Shirodkar, P., Macrae, C. J., Meng, L. & Koch, C. A. The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair. Nucleic Acids Res. 41, 4080\u20134092 (2013).","journal-title":"Nucleic Acids Res."},{"key":"739_CR67","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi, R., Rondinelli, B. & D\u2019Andrea, A. D. Repair pathway choices and consequences at the double-stranded break. Trends Cell Biol. 26, 52\u201364 (2016).","journal-title":"Trends Cell Biol."},{"key":"739_CR68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07729-2","volume":"10","author":"G Balmus","year":"2019","unstructured":"Balmus, G. et al. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. Nat. Commun. 10, 87 (2019).","journal-title":"Nat. Commun."},{"key":"739_CR69","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nsmb991","volume":"12","author":"J Zhang","year":"2005","unstructured":"Zhang, J., Ma, Z., Treszezamsky, A. & Powell, S. N. MDC1 interacts with Rad51 and facilitates homologous recombination. Nat. Struct. Mol. Biol. 12, 902\u2013909 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"739_CR70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mrfmmm.2013.07.007","volume":"750","author":"R Scully","year":"2013","unstructured":"Scully, R. & Xie, A. Double strand break repair functions of histone H2AX. Mutat. Res. 750, 5\u201314 (2013).","journal-title":"Mutat. Res."},{"key":"739_CR71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"739_CR72","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1128\/MCB.02269-06","volume":"27","author":"N Iles","year":"2007","unstructured":"Iles, N., Rulten, S., El-Khamisy, S. F. & Caldecott, K. W. APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. Mol. Cell. Biol. 27, 3793\u20133803 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"739_CR73","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.dnarep.2007.10.008","volume":"7","author":"CJ Macrae","year":"2008","unstructured":"Macrae, C. J., McCulloch, R. D., Ylanko, J., Durocher, D. & Koch, C. A. APLF (C2orf13) facilitates nonhomologous end-joining and undergoes ATM-dependent hyperphosphorylation following ionizing radiation. DNA Repair 7, 292\u2013302 (2008).","journal-title":"DNA Repair"},{"key":"739_CR74","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","volume":"31","author":"KT Flaherty","year":"2013","unstructured":"Flaherty, K. T. et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol. 31, 373\u2013379 (2013).","journal-title":"J. Clin. Oncol."},{"key":"739_CR75","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-14-0093","volume":"20","author":"MA Wilson","year":"2014","unstructured":"Wilson, M. A. et al. Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib. Clin. Cancer Res. 20, 3328\u20133337 (2014).","journal-title":"Clin. Cancer Res."},{"key":"739_CR76","first-page":"2094","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei, S. et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Clin. Cancer Res. 80, 2094\u20132100 (2020).","journal-title":"Clin. Cancer Res."},{"key":"739_CR77","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. 43, 11.10.1\u201333 (2013).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"739_CR78","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/bioinformatics\/btr446","volume":"27","author":"K Cibulskis","year":"2011","unstructured":"Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601\u20132602 (2011).","journal-title":"Bioinformatics"},{"key":"739_CR79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"739_CR80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"739_CR81","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).","journal-title":"Nucleic Acids Res."},{"key":"739_CR82","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"739_CR83","doi-asserted-by":"crossref","first-page":"283ra54","DOI":"10.1126\/scitranslmed.aaa1408","volume":"7","author":"N McGranahan","year":"2015","unstructured":"McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).","journal-title":"Sci. Transl. Med."},{"key":"739_CR84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"739_CR85","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","volume":"33","author":"JR Conway","year":"2017","unstructured":"Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938\u20132940 (2017).","journal-title":"Bioinformatics"},{"key":"739_CR86","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e16 (2017).","journal-title":"Cell"},{"key":"739_CR87","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).","journal-title":"Sci. Transl. Med."},{"key":"739_CR88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"739_CR89","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","volume":"10","author":"SJ Rodig","year":"2018","unstructured":"Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018).","journal-title":"Sci. Transl. Med."},{"key":"739_CR90","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1101\/gr.115907.110","volume":"21","author":"RE Mills","year":"2011","unstructured":"Mills, R. E. et al. Natural genetic variation caused by small insertions and deletions in the human genome. Genome Res. 21, 830\u2013839 (2011).","journal-title":"Genome Res."},{"key":"739_CR91","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"739_CR92","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.3885","volume":"13","author":"N Ignatiadis","year":"2016","unstructured":"Ignatiadis, N., Klaus, B., Zaugg, J. B. & Huber, W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat. Methods 13, 577\u2013580 (2016).","journal-title":"Nat. Methods"},{"key":"739_CR93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"739_CR94","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"739_CR95","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"739_CR96","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","volume":"14","author":"KA Rauen","year":"2013","unstructured":"Rauen, K. A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 14, 355\u2013369 (2013).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"739_CR97","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/nar\/gkq1156","volume":"39","author":"A Kamburov","year":"2011","unstructured":"Kamburov, A. et al. ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res. 39, 712\u2013717 (2011).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41588-020-00739-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41588-020-00739-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41588-020-00739-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T18:20:27Z","timestamp":1723918827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-020-00739-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":97,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1038\/s41588-020-00739-1","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.V.A. is a consultant for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Monte Rosa Therapeutics, Manifold Bio and Janssen, provides research support to Novartis and Bristol-Myers Squibb, has equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Monte Rosa Therapeutics and Microsoft, receives travel reimbursement from Roche\/Genentech, and has institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}